Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

On Wednesday, Lilly said Zepbound would be sold directly in Walmart pharmacies for $349 to $499 a month. Next year, Lilly is ...

Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

As weight loss market rival Novo Nordisk drew headlines for starting a bidding war over a potential $9bn acquisition of ...

Lilly predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...

Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and ...